↓ Skip to main content

Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma

Overview of attention for article published in Journal of Hematology & Oncology, December 2014
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (55th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
30 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma
Published in
Journal of Hematology & Oncology, December 2014
DOI 10.1186/s13045-014-0091-3
Pubmed ID
Authors

Debra Ehrlich, Bo Wang, Wei Lu, Peter Dowling, Ruirong Yuan

Abstract

BackgroundMost patients with small cell lung cancer (SCLC) or neuroblastoma (NB) already show clinically detectable metastases at diagnosis and have an extremely poor prognosis even when treated with combined modalities. The HuD-antigen is a neuronal RNA-binding protein that is expressed in 100% of SCLC tumor cells and over 50% of neuroblastoma cells. The correlation between high titers of circulating anti-HuD antibodies in patients and spontaneous tumor remission suggests that the HuD-antigen might be a potential molecular target for immunotherapy.MethodsWe have constructed a new antibody-toxin compound (called BW-2) by assembling a mouse anti-human-HuD monoclonal antibody onto streptavidin/saporin complexes.ResultsWe found that the immunotoxin BW-2 specifically killed HuD-positive human SCLC and NB cancer cells at very low concentrations in vitro. Moreover, intratumoral immunotoxin therapy in a nude mouse model of human SCLC (n¿=¿6) significantly reduced local tumor progression without causing toxicity. When the same intratumoral immunotoxin protocol was applied to an immunocompetent A/J mouse model of NB, significant inhibition of local tumor growth was also observed. In neuroblastoma allografted A/J mice (n¿=¿5) treated twice with intratumoral immunotoxin, significant tumor regression occurred in over 80% of the animals and their duration of tumor response was significantly prolonged.ConclusionsOur study suggests that anti-HuD based immunotoxin therapy may prove to be an effective alternative treatment for patients with SCLC and NB.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Portugal 1 3%
Unknown 29 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 20%
Student > Master 5 17%
Student > Ph. D. Student 5 17%
Student > Bachelor 4 13%
Student > Doctoral Student 2 7%
Other 2 7%
Unknown 6 20%
Readers by discipline Count As %
Medicine and Dentistry 5 17%
Agricultural and Biological Sciences 5 17%
Biochemistry, Genetics and Molecular Biology 4 13%
Computer Science 2 7%
Chemistry 2 7%
Other 5 17%
Unknown 7 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 November 2015.
All research outputs
#2,695,872
of 6,535,212 outputs
Outputs from Journal of Hematology & Oncology
#88
of 276 outputs
Outputs of similar age
#86,027
of 208,044 outputs
Outputs of similar age from Journal of Hematology & Oncology
#2
of 14 outputs
Altmetric has tracked 6,535,212 research outputs across all sources so far. This one has received more attention than most of these and is in the 56th percentile.
So far Altmetric has tracked 276 research outputs from this source. They receive a mean Attention Score of 2.1. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 208,044 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.